ICN Profit Drops 32% as Sales Fall
ICN Pharmaceuticals Inc. said second-quarter earnings fell 32% as royalties decreased for its biggest product, the hepatitis C drug ribavirin.
Net income fell to $21 million, or 26 cents a share, from $31 million, or 38 cents, a year earlier. The Costa Mesa drug maker was expected to earn 24 cents a share, according to a survey by First Call/Thomson Financial. Revenue increased 7% to $206 million.
ICN shares rose 89 cents to $32 on the New York Stock Exchange.
Ribavirin royalties fell 27% to $31 million, as doctors held off prescribing the drug, which is sold only in combination with Schering-Plough Corp.’s injectable interferon drug, Intron A, to treat the liver disease. Doctors have been waiting for U.S. regulators to approve a combination with an improved version of its Intron A, known as Peg-Intron, and ribavirin.
ICN Chairman Milan Panic lowered his estimate of ribavirin royalties for the year to between $160 million and $180 million from the $180-million-to-$190-million range in January.
Even the lowered forecast “is an aggressive target [and] implies a significant ramp-up in the second half,” said First Union Securities analyst Michael Tong.
Last week, Schering-Plough won approval from the U.S. Food and Drug Administration to market ribavirin and Intron A separately.
Ribavirin capsules, sold as Rebetol, are expected to be available in the next few months.
ICN could realize royalty revenue of about $300 million from ribavirin next year, said Arnhold & S. Bleichroeder analyst Richard Stover.
Higher revenue from ICN’s specialty-pharmaceutical business along with a growing market for hepatitis C drugs, “gives confidence to the outlook for improving earnings beginning in the fourth quarter,” Stover said.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.